MARKET

ARCT

ARCT

Arcturus Therape
NASDAQ
28.52
+1.46
+5.40%
Opening 13:41 04/23 EDT
OPEN
27.03
PREV CLOSE
27.06
HIGH
28.65
LOW
27.03
VOLUME
130.35K
TURNOVER
0
52 WEEK HIGH
43.81
52 WEEK LOW
17.52
MARKET CAP
767.62M
P/E (TTM)
-25.5487
1D
5D
1M
3M
1Y
5Y
Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Arcturus Therapeutics' ARCT-032 gene therapy for cystic fibrosis has been designated as an "orphan drug" in the U.S. And Europe. The therapy has the potential to generate significant revenues, similar to Vertex Pharmaceuticals' Trikafta treatment. Arcturus has a potential to become profitable with the success of their other therapies.
Seeking Alpha · 10h ago
Weekly Report: what happened at ARCT last week (0415-0419)?
Weekly Report · 1d ago
Analysts’ Top Healthcare Picks: Elevance Health (ELV), Argenx Se (ARGX)
TipRanks · 4d ago
As more rare disease therapies launch, their prices are rising
Therapies that treat rare diseases are among the most expensive treatments for patients. The most expensive medicine in the world, Lenmeldy, comes with a wholesale price of $4.25M. Cantor Fitzgerald says the prices of rare disease therapies have been increasing since 2021.
Seeking Alpha · 04/16 16:22
Weekly Report: what happened at ARCT last week (0408-0412)?
Weekly Report · 04/15 11:59
Weekly Report: what happened at ARCT last week (0401-0405)?
Weekly Report · 04/08 12:05
Weekly Report: what happened at ARCT last week (0325-0329)?
Weekly Report · 04/01 12:02
Buy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline Progress
TipRanks · 04/01 11:15
More
About ARCT
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.

Webull offers Arcturus Therapeutics Holdings Inc stock information, including NASDAQ: ARCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARCT stock methods without spending real money on the virtual paper trading platform.